看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | No | No |
| Is net profit margin increasing? | No | No |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| Gilead Sciences, Inc. |
| Amgen Inc. |
| Biogen Inc. |
| Arcutis Biotherapeutics, Inc. |
| Vanda Pharmaceuticals Inc. |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| GILD | AMGN | BIIB | ARQT | VNDA | 4AB | |||
| Return On Equity | ||||||||
| Latest Twelve Months | 2% | 68% | 10% | -114% | -3% | 62% | ||
| Fiscal Year - 1 | 26% | 136% | 8% | -176% | 0% | 35% | ||
| Fiscal Year - 2 | 22% | 126% | 25% | -123% | 1% | 72% | ||
| Fiscal Year - 3 | 32% | 73% | 14% | NA | 7% | 81% | ||
| Fiscal Year - 4 | 1% | 76% | 33% | NA | 5% | 186% | ||
| Fiscal Year - 5 | 25% | 71% | 45% | NA | 34% | -94% | ||
| Average | 18% | 92% | 23% | -137% | 7% | 57% | ||
| Median | 23% | 75% | 20% | -123% | 3% | 67% | ||
| Benchmarks | Ticker | |||||||
| Gilead Sciences, Inc. | NasdaqGS:GILD | |||||||
| Amgen Inc. | NasdaqGS:AMGN | |||||||
| Biogen Inc. | NasdaqGS:BIIB | |||||||
| Arcutis Biotherapeutics, Inc. | NasdaqGS:ARQT | |||||||
| Vanda Pharmaceuticals Inc. | NasdaqGM:VNDA | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | GILD | AMGN | BIIB | ARQT | VNDA | 4AB | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 28,754 | 33,424 | 9,676 | 197 | 199 | 56,334 | ||
| Fiscal Year | 28,754 | 33,424 | 9,676 | 197 | 199 | 56,334 | ||
| Fiscal Year - 1 | 27,116 | 28,190 | 9,836 | 60 | 193 | 54,318 | ||
| Fiscal Year - 2 | 27,281 | 26,323 | 10,173 | 4 | 254 | 58,054 | ||
| Fiscal Year - 3 | 27,305 | 25,979 | 10,982 | NA | 269 | 56,197 | ||
| Fiscal Year - 4 | 24,689 | 25,424 | 13,445 | NA | 248 | 45,804 | ||
| Fiscal Year - 5 | 22,449 | 23,362 | 14,378 | NA | 227 | 33,266 | ||
| Net Income | ||||||||
| Latest Twelve Months | 480 | 4,090 | 1,632 | (140) | (19) | 4,238 | ||
| Fiscal Year | 480 | 4,090 | 1,632 | (140) | (19) | 4,238 | ||
| Fiscal Year - 1 | 5,665 | 6,717 | 1,161 | (262) | 3 | 4,820 | ||
| Fiscal Year - 2 | 4,592 | 6,552 | 3,047 | (311) | 6 | 11,782 | ||
| Fiscal Year - 3 | 6,225 | 5,893 | 1,556 | (206) | 33 | 11,468 | ||
| Fiscal Year - 4 | 123 | 7,264 | 4,001 | (136) | 23 | 4,556 | ||
| Fiscal Year - 5 | 5,386 | 7,842 | 5,889 | (42) | 116 | 7,842 | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 62,125 | 97,154 | 26,845 | 341 | 648 | 134,711 | ||
| Latest Fiscal Quarter | 58,995 | 91,839 | 28,049 | 349 | 656 | 135,161 | ||
| Fiscal Year | 58,995 | 91,839 | 28,049 | 349 | 656 | 135,161 | ||
| Fiscal Year - 1 | 62,125 | 97,154 | 26,845 | 341 | 648 | 134,711 | ||
| Fiscal Year - 2 | 63,171 | 65,121 | 24,554 | 449 | 634 | 138,805 | ||
| Fiscal Year - 3 | 67,952 | 61,165 | 23,877 | 408 | 594 | 146,529 | ||
| Fiscal Year - 4 | 68,407 | 62,948 | 24,619 | 298 | 533 | 150,565 | ||
| Fiscal Year - 5 | 61,627 | 59,707 | 27,234 | 107 | 484 | 89,115 | ||
| Fiscal Year - 6 | 63,675 | 66,416 | 25,289 | 51 | 332 | 59,352 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 22,833 | 6,232 | 14,799 | 89 | 545 | 10,360 | ||
| Latest Fiscal Quarter | 19,330 | 5,877 | 16,716 | 158 | 539 | 3,325 | ||
| Fiscal Year | 19,330 | 5,877 | 16,716 | 158 | 539 | 3,325 | ||
| Fiscal Year - 1 | 22,833 | 6,232 | 14,799 | 89 | 545 | 10,360 | ||
| Fiscal Year - 2 | 21,240 | 3,661 | 13,398 | 210 | 527 | 17,254 | ||
| Fiscal Year - 3 | 21,069 | 6,700 | 10,896 | 298 | 505 | 15,408 | ||
| Fiscal Year - 4 | 18,202 | 9,409 | 10,700 | 271 | 453 | 13,076 | ||
| Fiscal Year - 5 | 22,525 | 9,673 | 13,343 | (65) | 411 | (8,172) | ||
| Fiscal Year - 6 | 21,387 | 12,500 | 13,040 | (24) | 275 | (8,446) | ||